Liquidia Technologies

About:

Liquidia Technologies is a clinical biopharmaceutical company focused on the development and commercialization of human therapeutics.

Website: http://www.liquidia.com

Twitter/X: Liquidia_Inc

Top Investors: Siemens, New Enterprise Associates, HealthCare Royalty Partners, Samsara BioCapital, Patient Square Capital

Description:

Liquidia Technologies is a late-stage clinical biopharmaceutical company focused on the development and commercialization of human therapeutics using our proprietary PRINT technology to transform the lives of patients. PRINT technology is a particle engineering platform that enables the precise production of uniform drug particles designed to improve the safety, efficacy, and performance of a wide range of therapies. Currently, Liquidia is developing two product candidates from its own pipeline: LIQ861 for the treatment of pulmonary arterial hypertension (PAH) and LIQ865 for the treatment of local post-operative pain. In addition to developing our own product candidates, Liquidia collaborates with leading pharmaceutical companies to apply our PRINT technology across a wide range of therapeutic areas, molecule types, and routes of administration.